A comprehensive review of published evidence regarding GLP-1R agonists in stroke reduction highlights several randomized control trials (Lixisnatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome, Liraglutide and Cardiovascular Outcomes in Type 2 diabetes [LEADER], Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes [SUSTAIN], Effects of Once Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes, and Albiglutide and Cardiovascular Outcomes in Patients with Type 2 diabetes and Cardiovascular Disease) and multiple meta-analyses. Here, GLP1R is linked to type 2 diabetes mellitus.